To combine MAGL inhibition with potentially enhanced uptake by highly glycolytic cancer cells, we designed glycoconjugated analogs of a <i>N</i>-benzoylpiperidine MAGL inhibitor scaffold bearing a glucopyranose unit. This evidence concerns the gene MGLL and cancer.